Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | AGER | Q15109 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490031 | 0.80 | KDM4E (0.53) | MAPTKDM4EALDH1A1ALOX15CYP3A4 | |
| SCHEMBL3573444 | 0.78 | KDM4E (0.55) | MAPTKDM4EALDH1A1ALOX15CYP3A4 | |
| SCHEMBL23931860 | 0.78 | KDM4E (0.55) | MAPTKDM4EALDH1A1ALOX15CYP3A4 | |
| SCHEMBL22523089 | 0.78 | KDM4E (0.55) | MAPTKDM4EALDH1A1ALOX15CYP3A4 | |
| SCHEMBL23486417 | 0.77 | FABP4 (0.46) | DHODHMAPTKDM4EALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL22365731 | 0.76 | KDM4E (0.53) | MAPTKDM4EALDH1A1ALOX15CYP3A4 | |
| SCHEMBL4134533 | 0.76 | DHODH (0.62) | DHODHMAPTKDM4EALDH1A1ALOX15 | |
| SCHEMBL27874235 | 0.76 | KDR (0.63) | MAPTKDM4EALDH1A1CYP3A4MEN1 | |
| SCHEMBL3573826 | 0.75 | KMT2A (0.57) | MAPTKDM4EALDH1A1ALOX15CYP3A4 | |
| SCHEMBL9452421 | 0.74 | KDM4E (0.50) | MAPTKDM4EALDH1A1ALOX15CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12515207-B2 | Metal-metal bonded ammonia oxidation catalysts | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-01-06 | — | — | US | disclosed |
| CN-119836304-A | Oral dosage form containing ion chargeable hydrogel for delivering active agent | 恩特雷加公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119792235-A | Apigenin delivery composite material containing linseed gum oligosaccharide and preparation method and application thereof | 中国农业科学院油料作物研究所 | 2025-04-11 | — | — | CN | disclosed |
| CN-119677515-A | Treatment of fibrotic diseases using metabotropic glutamate receptor 5 antagonists or/and cannabinoid receptor 1 antagonists | 美国政府健康及人类服务部 | 2025-03-21 | — | — | CN | disclosed |
| CN-118922189-A | Novel prodrugs derived from niacin and ribose | 线粒体能量有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118161673-A | Catheter lock solution incorporating nitric oxide releasing liposomes | 贝克顿·迪金森公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2024-02-15 | — | — | US | disclosed |
| EP-4313067-A1 | TREATMENT OF IMMUNE-RELATED DISORDERS, KIDNEY DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS, AND OXIDATIVE STRESS-ASSOCIATED DISORDERS USING NRH, NARH AND REDUCED DERIVATIVES THEREOF | Mitopower LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2018106632-A1 | DERMAL AND TRANSDERMAL ADMINISTRATION OF TREPROSTINIL AND SALTS THEREOF | Corsair Pharma, Inc. (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-3242688-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. | 2016-07-14 | — | — | US | disclosed |
| WO-2016111834-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-8802703-B2 | Arylamino N-heteraryl compounds as MEK inhibitors | MERCK SERONO S.A. (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20100256149-A1 | NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | US | disclosed |
| US-7772233-B2 | Arylamino N-heteroaryl compounds as MEK inhibitors | Merck Serono, S.A. (CH) | 2010-08-10 | — | — | US | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20070287709-A1 | Novel arylamino N-heteraryls as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| WO-2007123939-A2 | NOVEL ARYLAMINO N-HETERARYLS AS MEK INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | DHODH 306/4885MAPT 677/4885KDM4E 3520/4885 |
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | PTGS2, PTGES2, TOP2A | DHODH 522/4885MAPT 4235/4885KDM4E 3276/4885 |
| US-20100256149-A1 | NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS | NRAS, MAP3K19, MAP3K20 | DHODH 1535/4885MAPT 4515/4885KDM4E 1453/4885 |
| US-20070287709-A1 | Novel arylamino N-heteraryls as MEK inhibitors | NRAS, MAP3K19, MAP3K1 | DHODH 1588/4885MAPT 4512/4885KDM4E 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.